RxDoctor Payments Data

Shann Mika Ruiz

Nurse Practitioner · Stanford, CANPI 1689140139

Payments from drug & device makers

$1,052in general payments, 2019–2025

Across 14 payments — averaging $75.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$239
  • Agios Pharmaceuticals, Inc.$125
  • Eisai Inc.$125
  • Exact Sciences$124
  • Lexicon Pharmaceuticals, Inc.$124
  • Johnson & Johnson$115
  • plus $200 from 4 others

What the payments were for

  • Food & beverage$1,01697%
  • Education$363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,052 in reported general payments places this provider in the 80th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$65,950
Medicare patients
209
Services billed
408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
InlytaAxitinib43$738,488
CabometyxCabozantinib S-Malate27$661,437
XtandiEnzalutamide38$500,098
NubeqaDarolutamide29$359,062
WeliregBelzutifan13$307,545
Abiraterone Acetate170$212,981
OrgovyxRelugolix61$162,181
ErleadaApalutamide12$138,294
EliquisApixaban18$17,753
MyrbetriqMirabegron11$8,463
XareltoRivaroxaban13$7,710
Prednisone229$953
Tamsulosin Hcl21$486
Bicalutamide17$411
Ondansetron Hcl27$290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerInlyta, Eliquis$36$756,24161 claims
BayerNubeqa$57$359,06229 claims
MerckWelireg$79$307,54513 claims
Johnson & JohnsonErleada, Xarelto$115$146,00425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →